Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As COVID-19 infections begin to rise again, a novel testing strategy proposed by researchers at the University of Oxford at the start of the pandemic has become urgent once again.

Healthcare worker wearing full PPE collects a sample at a coronavirus mobile testing unit

The strategy aims to bring the virus’s reproduction number (‘R’) down to below 1, by concentrating testing resources on particular groups in the population that are most likely to spread the infection to others, rather than testing the general population at random.

‘Governments around the world are looking for a testing strategy for COVID-19. This strategy will inevitably be constrained by our testing capacity: in short, every person in the world cannot be tested every day,’ says co-author Dr Daniel Susskind, Fellow of Economics at Balliol College, Oxford. ‘Given these constraints, which still bind us many months into this crisis, we need to focus again on a testing strategy that is workable, efficient and affordable for the government.’

The proposed strategy is predicated on the understanding that not everyone is equally likely to spread COVID-19. An individual’s likelihood of infecting others will depend on their occupation, geography, and other behaviours when not isolated.

The full story is available on the University of Oxford website

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.